Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT) - PubMed (original) (raw)

Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT)

D J Chaplin. Br J Cancer. 1986 Nov.

Free PMC article

Abstract

It is known that many solid animal tumours have a lower oxygenation level than most normal tissues and, in addition, that this level of oxygenation can be further decreased by systemic administration of 5-hydroxytryptamine (5-HT). The present study has investigated if such selective decrease in tumour oxygenation can be exploited by using the hypoxic cell cytotoxin, RSU-1069. The results obtained show that 5-HT at a dose of 5 mg kg-1, although not cytotoxic alone, can potentiate the cytotoxic effects of RSU-1069 in the Lewis lung carcinoma over the dose range 0.01-0.15 mg g-1. Maximum potentiation occurs when 5-HT is administered after RSU-1069. Potentiation of RSU-1069 cytotoxicity was observed using both the soft agar excision assay as an endpoint as well as in situ growth delay. In addition, the study shows that potentiation of RSU-1069 (0.1 mg g-1) cytotoxicity can be seen with 5-HT doses as low as 0.5 mg kg-1. In contrast to the tumour cytotoxicity results, 5-HT at a dose of 5 mg kg-1 i.p. did not affect the systemic toxicity, as measured by LD50/7d of RSU-1069. Thus, these results indicate that 5-HT can increase the therapeutic efficiency of RSU-1069. Such a finding is consistent with the rationale that selective reduction in tumour blood flow and oxygenation induced by 5-HT can be exploited using the hypoxic cell cytotoxin RSU-1069.

PubMed Disclaimer

Similar articles

• The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
  Chaplin DJ, Acker B. Chaplin DJ, et al. Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):579-85. doi: 10.1016/0360-3016(87)90075-7. Int J Radiat Oncol Biol Phys. 1987. PMID: 3558048
• Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.
  Wong KH, Koch CJ, Wallen CA, Wheeler KT. Wong KH, et al. Br J Cancer. 1991 Apr;63(4):484-8. doi: 10.1038/bjc.1991.116. Br J Cancer. 1991. PMID: 2021530 Free PMC article.
• RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.
  Adams GE, Ahmed I, Sheldon PW, Stratford IJ. Adams GE, et al. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1653-6. doi: 10.1016/0360-3016(84)90521-2. Int J Radiat Oncol Biol Phys. 1984. PMID: 6548211
• The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model.
  Siemann DW. Siemann DW. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1115-8. doi: 10.1016/0360-3016(89)90929-2. Int J Radiat Oncol Biol Phys. 1989. PMID: 2703392
• Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
  Hill RP, Gulyas S, Whitmore GF. Hill RP, et al. Br J Cancer. 1986 Jun;53(6):743-51. doi: 10.1038/bjc.1986.128. Br J Cancer. 1986. PMID: 3755053 Free PMC article.

Cited by

• A Tumor Vascular-Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia.
  Luan X, Guan YY, Liu HJ, Lu Q, Zhao M, Sun D, Lovell JF, Sun P, Chen HZ, Fang C. Luan X, et al. Adv Sci (Weinh). 2018 May 28;5(8):1800034. doi: 10.1002/advs.201800034. eCollection 2018 Aug. Adv Sci (Weinh). 2018. PMID: 30128230 Free PMC article.
• Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
  Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Lash CJ, et al. Br J Cancer. 1998 Aug;78(4):439-45. doi: 10.1038/bjc.1998.512. Br J Cancer. 1998. PMID: 9716024 Free PMC article.
• Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
  Butler SA, Wood PJ, Cole S, Williams C, Adams GE, Stratford IJ. Butler SA, et al. Br J Cancer. 1997;76(4):438-44. doi: 10.1038/bjc.1997.407. Br J Cancer. 1997. PMID: 9275019 Free PMC article.
• Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).
  Denny WA, Wilson WR. Denny WA, et al. Cancer Metastasis Rev. 1993 Jun;12(2):135-51. doi: 10.1007/BF00689806. Cancer Metastasis Rev. 1993. PMID: 8375017 Review.

References

1. 1. Br J Cancer. 1986 Mar;53(3):339-44 - PubMed
2. 1. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1091-5 - PubMed
3. 1. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1239-42 - PubMed
4. 1. J Natl Cancer Inst. 1951 Oct;12(2):399-421 - PubMed
5. 1. Acta radiol. 1962 Dec;58:401-34 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Medical

  • MedlinePlus Health Information